{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:10:53Z","timestamp":1785449453073,"version":"3.56.0"},"reference-count":61,"publisher":"BMJ","issue":"Suppl 2","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-003239"],"award-info":[{"award-number":["INV-003239"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ EBM"],"accepted":{"date-parts":[[2025,2,28]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>An increasing investment in health technology assessment (HTA) in low-income and middle-income countries has generated greater interest from policy-makers about the value and return on investment (ROI) of HTA. Few studies have, however, quantified the benefits of HTA in terms of its value to the health system. This evaluation aims to quantify the impact and ROI achieved by the HTA agency in India (HTAIn).<\/jats:p>\n                  <jats:p>A framework developed by the University of Glasgow was used to review three \u2018hta\u2019s commissioned by HTAIn between 2018 and 2020, taking into account the opportunity cost of investing in these processes. Costs included fixed costs for HTAIn and costs for undertaking each \u2018hta\u2019. Attributable benefits are calculated by subtracting the counterfactual (benefits that might have been realised without an HTA) from realised benefits.<\/jats:p>\n                  <jats:p>HTAIn sits under the Department of Health Research, Ministry of Health and Family Welfare, Government of India. It was set up to facilitate the process of transparent and evidence-informed decision-making in healthcare in India.<\/jats:p>\n                  <jats:p>HTA helps decision-makers to understand the consequences of alternative courses of action and to select the options that produce the best outcomes at the lowest cost. Institutionalisation of HTA is seen as pivotal to supporting universal health coverage as a means of supporting a better allocation of finite resources, cost containment and the maximisation of health.<\/jats:p>\n                  <jats:p>Net health benefits are our measure of value. The ROI of HTAIn is calculated by aggregating attributable benefits and offsetting them against the costs of investment.<\/jats:p>\n                  <jats:p>Our findings show that investing in HTAIn yields a return of 9:1, with potential to increase to 71:1 with full implementation of HTA recommendations. Variability of ROI ranged from 5:1 to 40:1 between the different interventions and diseases.<\/jats:p>\n                  <jats:p>While HTAIn requires financial investment, it is an efficient use of resources. The potential for greater impact and the variability of the ROI between interventions underline the importance of planning for implementation and good topic selection in HTA.<\/jats:p>","DOI":"10.1136\/bmjebm-2023-112487","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T16:11:04Z","timestamp":1742487064000},"page":"s29-s37","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Is health technology assessment value for money? Estimating the return on investment of health technology assessment in India (HTAIn)"],"prefix":"10.1136","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9952-6077","authenticated-orcid":false,"given":"Pankaj","family":"Bahuguna","sequence":"first","affiliation":[{"name":"School of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9028-9976","authenticated-orcid":false,"given":"Peter Alan","family":"Baker","sequence":"additional","affiliation":[{"name":"Global Health Policy Program, Center for Global Development, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Briggs","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gulliver","sequence":"additional","affiliation":[{"name":"Global Health Policy Program, Center for Global Development, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Hesselgreaves","sequence":"additional","affiliation":[{"name":"Newcastle Business School, Northumbria University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3045-1649","authenticated-orcid":false,"given":"Abha","family":"Mehndiratta","sequence":"additional","affiliation":[{"name":"Center for Global Development, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5183-3959","authenticated-orcid":false,"given":"Francis","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Guzman","sequence":"additional","affiliation":[{"name":"Global Health Policy Program, Center for Global Development, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4115-2882","authenticated-orcid":false,"given":"Eleanor","family":"Grieve","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"2025112607301104000_30.Suppl_2.s29.1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462320000215"},{"key":"2025112607301104000_30.Suppl_2.s29.2","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7547-1-8"},{"key":"2025112607301104000_30.Suppl_2.s29.3","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S0140-6736(15)60097-6","article-title":"Disease Control Priorities, 3rd edition: improving health and reducing poverty","volume":"391","author":"Jamison","year":"2018","journal-title":"The Lancet"},{"key":"2025112607301104000_30.Suppl_2.s29.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12962-021-00290-8","article-title":"Assessing the performance of health technology assessment (HTA) agencies: developing a multi-country, multi-stakeholder, and multi-dimensional framework to explore mechanisms of impact","volume":"19","author":"Millar","year":"2021","journal-title":"Cost Eff Resour Alloc"},{"key":"2025112607301104000_30.Suppl_2.s29.5","doi-asserted-by":"crossref","DOI":"10.1017\/S0266462323002763","article-title":"The value and impact of health technology assessment: discussions and recommendations from the 2023 Health Technology Assessment International Global Policy Forum","volume":"39","author":"Trowman","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"key":"2025112607301104000_30.Suppl_2.s29.6","doi-asserted-by":"crossref","DOI":"10.1016\/j.hpopen.2020.100004","article-title":"Building Capacity for Evidence-Informed Priority Setting in the Indian Health System: An International Collaborative Experience","volume":"1","author":"Downey","year":"2020","journal-title":"Health Policy Open"},{"key":"2025112607301104000_30.Suppl_2.s29.7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s41669-017-0037-0","article-title":"Health Technology Assessment for Policy Making in India: Current Scenario and Way Forward","volume":"2","author":"Prinja","year":"2018","journal-title":"Pharmacoecon Open"},{"key":"2025112607301104000_30.Suppl_2.s29.8","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_115_19"},{"key":"2025112607301104000_30.Suppl_2.s29.9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40258-020-00631-3","article-title":"Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India\u2019s National Publicly Financed Health Insurance Scheme","volume":"19","author":"Prinja","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"2025112607301104000_30.Suppl_2.s29.10","unstructured":"Gerhardus A , Dorendorf E , R\u00f8ttingen J-A , et al . What are the effects of hta reports on the health system? Evidence from the research literature. Health technology assessment and health policy-making in Europe. 2008.109."},{"key":"2025112607301104000_30.Suppl_2.s29.11","unstructured":"Grieve E . Conceptualising, measuring and valuing the impact of health technology assessment. University of Glasgow, 2020."},{"key":"2025112607301104000_30.Suppl_2.s29.12","doi-asserted-by":"publisher","DOI":"10.3310\/hta20220"},{"key":"2025112607301104000_30.Suppl_2.s29.13","unstructured":"Wilsdon T , Serota A . A comparative analysis of the role and impact of health technology assessment. London: Charles River Associates, 2011."},{"key":"2025112607301104000_30.Suppl_2.s29.14","doi-asserted-by":"crossref","first-page":"100688","DOI":"10.1016\/j.hlpt.2022.100688","article-title":"Impact of health technology assessment implementation with a special focus on middle-income countries","volume":"11","author":"Fasseeh","year":"2022","journal-title":"Health Policy Technol"},{"key":"2025112607301104000_30.Suppl_2.s29.15","unstructured":"Guthrie S , Wamae W , Diepeveen S , et al . Measuring research: a guide to research evaluation frameworks and tools. Cambridge: RAND Europe, 2013."},{"key":"2025112607301104000_30.Suppl_2.s29.16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1017\/S0266462307080105","article-title":"Assessing the performance of health technology assessment organizations: a framework","volume":"24","author":"Lafortune","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"key":"2025112607301104000_30.Suppl_2.s29.17","unstructured":"Wanke M . An exploratory review of evaluations of health technology assessment agencies. Alberta Heritage Foundation for Medical Research (AHFMR) HTA Initiative #16; 2006."},{"key":"2025112607301104000_30.Suppl_2.s29.18","unstructured":"INAHTA . INAHTA impact framework. Available: https:\/\/www.inahta.org\/hta-tools-resources\/briefs\/#Impact [Accessed 18 Apr 2023]."},{"key":"2025112607301104000_30.Suppl_2.s29.19","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462300010242"},{"key":"2025112607301104000_30.Suppl_2.s29.20","doi-asserted-by":"crossref","DOI":"10.1017\/S0266462322000277","article-title":"A model-based study to estimate the health and economic impact of health technology assessment in Thailand","volume":"38","author":"Kingkaew","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"key":"2025112607301104000_30.Suppl_2.s29.21","article-title":"Returns on Research Funded Under the NIHR Health Technology Assessment (HTA) Programme: Economic Analysis and Case Studies","volume":"5","author":"Guthrie","year":"2016","journal-title":"Rand Health Q"},{"key":"2025112607301104000_30.Suppl_2.s29.22","doi-asserted-by":"publisher","DOI":"10.1177\/135581969600100107"},{"key":"2025112607301104000_30.Suppl_2.s29.23","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462300016172"},{"key":"2025112607301104000_30.Suppl_2.s29.24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1017\/S0266462308080355","article-title":"Assessing the impact of health technology assessment in the Netherlands","volume":"24","author":"Oortwijn","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"key":"2025112607301104000_30.Suppl_2.s29.25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1017\/S0266462312000748","article-title":"Assessing the impact of health technology assessment on the Austrian healthcare system","volume":"29","author":"Schumacher","year":"2013","journal-title":"Int J Technol Assess Health Care"},{"key":"2025112607301104000_30.Suppl_2.s29.26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1017\/S0266462319000011","article-title":"Outcomes and Impacts of 10-Year HTA Implementation in Taiwan","volume":"35","author":"Kao","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"key":"2025112607301104000_30.Suppl_2.s29.27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12961-018-0286-0","article-title":"Impact assessment of Iran\u2019s health technology assessment programme","volume":"16","author":"Yazdizadeh","year":"2018","journal-title":"Health Res Policy Sys"},{"key":"2025112607301104000_30.Suppl_2.s29.28","unstructured":"INAHTA . INAHTA impact assessment study 2020. Canada, 2020."},{"key":"2025112607301104000_30.Suppl_2.s29.29","unstructured":"The Global Fund . Seventh replenishment investment case fight for what counts. Available: https:\/\/www.theglobalfund.org\/en\/fight-for-what-counts [Accessed 3 Apr 2023]."},{"key":"2025112607301104000_30.Suppl_2.s29.30","unstructured":"iDSI . IDSI viewpoints: Indonesia- from collaboration to call for action. 2018. Available: http:\/\/www.globalhitap.net\/wp-content\/uploads\/2018\/12\/iDSI_Booklet_complete_15.1.19.pdf [Accessed 24 Jun 2023]."},{"key":"2025112607301104000_30.Suppl_2.s29.31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1017\/S0266462309090473","article-title":"Health technology assessment in Catalonia: an overview of past and future perspectives","volume":"25 Suppl 1","author":"de Sol\u00e0-Morales","year":"2009","journal-title":"Int J Technol Assess Health Care"},{"key":"2025112607301104000_30.Suppl_2.s29.32","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462300005481"},{"key":"2025112607301104000_30.Suppl_2.s29.33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s10198-001-0082-5","article-title":"Does health technology assessment benefit health services and politics? The experiences of an established HTA institution: the Danish Centre for Evaluation and HTA","volume":"3","author":"Sigmund","year":"2002","journal-title":"Eur J Health Econ"},{"key":"2025112607301104000_30.Suppl_2.s29.34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1017\/S0266462319000023","article-title":"Health Technology Assessment in Malaysia: Past, Present, and Future","volume":"35","author":"Roza","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"key":"2025112607301104000_30.Suppl_2.s29.35","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1017\/S0266462317000563","article-title":"A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND","volume":"33","author":"Lipska","year":"2017","journal-title":"Int J Technol Assess Health Care"},{"key":"2025112607301104000_30.Suppl_2.s29.36","unstructured":"NICE . Evaluation and review of nice implementation guidance. n.d. Available: http:\/\/webarchive.nationalarchives.gov.uk\/20080611105936\/http:\/\/www.nice.org.uk\/usingguidance\/evaluationandreviewofniceimplementationevidenceernie\/evaluation_and_review_of_nice_implementation_evidence_ernie.jsp"},{"key":"2025112607301104000_30.Suppl_2.s29.37","doi-asserted-by":"crossref","unstructured":"Grieve E , Bahuguna P , Gulliver S , et al . Estimating the return on investment of health technology assessment india (HTAIn). 2023. Available: https:\/\/www.cgdev.org\/publication\/estimating-return-investment-health-technology-assessment-india-htain","DOI":"10.1136\/bmjebm-2023-112487"},{"key":"2025112607301104000_30.Suppl_2.s29.38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2017-000607","article-title":"Supporting the development of a health benefits package in Malawi","volume":"3","author":"Ochalek","year":"2018","journal-title":"BMJ Glob Health"},{"key":"2025112607301104000_30.Suppl_2.s29.39","doi-asserted-by":"crossref","DOI":"10.1016\/j.lansea.2023.100241","article-title":"Development of the Indian Reference Case for undertaking economic evaluation for health technology assessment","volume":"16","author":"Sharma","year":"2023","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"2025112607301104000_30.Suppl_2.s29.40","unstructured":"MHFW . One hundred and nineteenth report on demand for grants 2020-21 (demand no.43) of department of health research, ministry of health and family welfare. Rajya Sabha Secretariat, New Delhi; 2020."},{"key":"2025112607301104000_30.Suppl_2.s29.41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s40944-021-00602-z","article-title":"Cervical Cancer: Formulation and Implementation of Govt of India Guidelines for Screening and Management","volume":"20","author":"Mehrotra","year":"2022","journal-title":"Indian J Gynecol Oncol"},{"key":"2025112607301104000_30.Suppl_2.s29.42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5588\/pha.20.0004","article-title":"Impact and operational feasibility of TrueNa tMTB\/Rif under India\u2019s RNTCP","volume":"10","author":"Jeyashree","year":"2020","journal-title":"Public Health Action"},{"key":"2025112607301104000_30.Suppl_2.s29.43","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31937"},{"key":"2025112607301104000_30.Suppl_2.s29.44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238291","article-title":"Cost effectiveness of strategies for cervical cancer prevention in India","volume":"15","author":"Chauhan","year":"2020","journal-title":"PLoS One"},{"key":"2025112607301104000_30.Suppl_2.s29.45","first-page":"334","article-title":"Injection practices in a metropolis of North India: perceptions, determinants and issues of safety","volume":"58","author":"Kotwal","year":"2004","journal-title":"Indian J Med Sci"},{"key":"2025112607301104000_30.Suppl_2.s29.46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/2224-3151.206931","article-title":"Injection practices in India","volume":"1","author":"Arora","year":"2012","journal-title":"WHO South East Asia J Public Health"},{"key":"2025112607301104000_30.Suppl_2.s29.47","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40258-019-00536-w","article-title":"Cost-Effectiveness of Therapeutic Use of Safety-Engineered Syringes in Healthcare Facilities in India","volume":"18","author":"Bahuguna","year":"2020","journal-title":"Appl Health Econ Health Policy"},{"key":"2025112607301104000_30.Suppl_2.s29.48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002149","article-title":"The Tuberculosis Cascade of Care in India\u2019s Public Sector: A Systematic Review and Meta-analysis","volume":"13","author":"Subbaraman","year":"2016","journal-title":"PLoS Med"},{"key":"2025112607301104000_30.Suppl_2.s29.49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218890","article-title":"Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India\u2019s public sector","volume":"14","author":"Lee","year":"2019","journal-title":"PLoS One"},{"key":"2025112607301104000_30.Suppl_2.s29.50","unstructured":"Rajsekar K , Tyagi K , Singh M . Rapid health technology assessment for incorporating TrueNat as a diagnostic tool for tuberculosis under RNTCP in India. New Delhi, India: Indian Council of Medical Research, 2019."},{"key":"2025112607301104000_30.Suppl_2.s29.51","unstructured":"iDSI . 2025. Available: https:\/\/www.cgdev.org\/blog\/building-institutions-priority-setting-health-six-lessons-10-years-idsi2024"},{"key":"2025112607301104000_30.Suppl_2.s29.52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2019.07.016","article-title":"The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review","volume":"23","author":"L\u00f6blov\u00e1","year":"2020","journal-title":"Value Health"},{"key":"2025112607301104000_30.Suppl_2.s29.53","unstructured":"WHO . 2015 Global survey on health technology assessment by national authorities. 2015."},{"key":"2025112607301104000_30.Suppl_2.s29.54","unstructured":"Lorenzoni L , Murtin F , Springare L-S , et al . Which policies increase value for money in health care? 2018."},{"key":"2025112607301104000_30.Suppl_2.s29.55","doi-asserted-by":"crossref","unstructured":"Ghosh S , Pramesh CS , Sengar M , et al . Exploring adaptive health technology assessment for evaluating 10 cancer interventions: insights and lessons from a pilot study in India. BMJ EBM 2025. doi:10.1136\/bmjebm-2023-112490","DOI":"10.1136\/bmjebm-2023-112490"},{"key":"2025112607301104000_30.Suppl_2.s29.56","doi-asserted-by":"crossref","unstructured":"Gheorghe A , Mehndiratta A , Baker P , et al . Measuring progress in institutionalising evidence-informed priority-setting in the Indian healthcare system: an application using the iProSE scale. BMJ EBM 2024. doi:10.1136\/bmjebm-2023-112485","DOI":"10.1136\/bmjebm-2023-112485"},{"key":"2025112607301104000_30.Suppl_2.s29.57","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-012798","article-title":"Analyses of the return on investment of public health interventions: a scoping review and recommendations for future studies","volume":"8","author":"Turner","year":"2023","journal-title":"BMJ Glob Health"},{"key":"2025112607301104000_30.Suppl_2.s29.58","unstructured":"D B. talking about the \u2018return on investment of public health\u2019: why it\u2019s important to get it right. 2018. Available: https:\/\/www.kingsfund.org.uk\/blog\/2018\/04\/return-investment-public-health [Accessed 22 Jun 2023]."},{"key":"2025112607301104000_30.Suppl_2.s29.59","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2750","article-title":"Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis","volume":"350","author":"Kontopantelis","year":"2015","journal-title":"BMJ"},{"key":"2025112607301104000_30.Suppl_2.s29.60","unstructured":"Cook T , Campbell D . Quasi-experimentation design & analysis issues for field settings. USA: Houghton Mifflin Company, 1979."},{"key":"2025112607301104000_30.Suppl_2.s29.61","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"}],"container-title":["BMJ Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjebm-2023-112487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:30:50Z","timestamp":1764171050000},"score":1,"resource":{"primary":{"URL":"https:\/\/ebm.bmj.com\/lookup\/doi\/10.1136\/bmjebm-2023-112487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":61,"journal-issue":{"issue":"Suppl 2","published-online":{"date-parts":[[2025,11,26]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjebm-2023-112487"],"URL":"https:\/\/doi.org\/10.1136\/bmjebm-2023-112487","relation":{},"ISSN":["2515-446X","2515-4478"],"issn-type":[{"value":"2515-446X","type":"print"},{"value":"2515-4478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}